US2472133A
(en)
|
1947-03-20 |
1949-06-07 |
Du Pont |
Thiophanthraquinone derivatives
|
SU1049490A1
(ru)
|
1982-05-18 |
1983-10-23 |
Ордена Трудового Красного Знамени Институт Химии Ан Мсср |
(3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
|
JPS6112632A
(ja)
*
|
1984-06-27 |
1986-01-21 |
Eisai Co Ltd |
脂溶性薬剤含有組成物
|
JPS6199787A
(ja)
|
1984-10-19 |
1986-05-17 |
株式会社日立製作所 |
バンド型配管支持装置
|
JPS63196576A
(ja)
|
1987-02-10 |
1988-08-15 |
Tetsuo Ikegawa |
フラルナフトキノン誘導体と制癌剤及びその製造方法
|
US5846534A
(en)
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
JPH04139177A
(ja)
|
1989-12-28 |
1992-05-13 |
Dainippon Ink & Chem Inc |
フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
|
DE69131856T2
(de)
|
1990-07-10 |
2000-06-15 |
Canon Kk |
Lichtempfindliches elektrophotographisches Element
|
TW252136B
(ja)
|
1992-10-08 |
1995-07-21 |
Ciba Geigy |
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
DE4322826A1
(de)
*
|
1993-07-08 |
1995-01-12 |
Galenik Labor Freiburg Gmbh |
Pharmazeutisches Präparat
|
US5595721A
(en)
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
GB9603507D0
(en)
|
1996-02-20 |
1996-04-17 |
Isis Innovation |
Antibody variants
|
JP3598168B2
(ja)
|
1996-03-18 |
2004-12-08 |
独立行政法人 科学技術振興機構 |
抗ウイルス剤
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
JPH1121284A
(ja)
|
1997-06-30 |
1999-01-26 |
Kotobuki:Kk |
フラノナフトキノン誘導体及びこれを含有する医薬
|
JPH1165141A
(ja)
|
1997-08-11 |
1999-03-05 |
Canon Inc |
電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
|
US6174913B1
(en)
|
1998-06-05 |
2001-01-16 |
The University Of North Carolina At Chapel Hill |
Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
EP1146869A2
(en)
|
1999-01-27 |
2001-10-24 |
University Of South Florida |
Inhibition of stat3 signal transduction for human cancer therapy
|
EP1897540A3
(en)
|
1999-01-27 |
2008-07-23 |
University Of South Florida |
Inhibition of STAT3 signal transduction for human cancer therapy
|
DK1169021T3
(da)
|
1999-04-01 |
2010-01-11 |
Hana Biosciences Inc |
Sammensætninger og fremgangsmåder til behandling af lymfom
|
US6482943B1
(en)
|
1999-04-30 |
2002-11-19 |
Slil Biomedical Corporation |
Quinones as disease therapies
|
JP3961827B2
(ja)
|
1999-08-02 |
2007-08-22 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規な選択的レチノイドアゴニスト
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
JP2001097860A
(ja)
|
1999-09-29 |
2001-04-10 |
Japan Science & Technology Corp |
抗薬剤耐性菌剤と抗クラミジア剤
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
KR20010100194A
(ko)
|
2000-03-13 |
2001-11-14 |
박호군 |
여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
|
EP1324771B2
(en)
|
2000-10-09 |
2018-06-06 |
CytomX Therapeutics, Inc. |
Therapeutic and tolerance inducing antibodies
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
WO2002078617A2
(en)
|
2001-03-28 |
2002-10-10 |
University Of South Florida |
Materials and methods for treatment of cancer and identification of anti-cancer compounds
|
GB0117696D0
(en)
|
2001-07-20 |
2001-09-12 |
Bradford Particle Design Plc |
Particle information
|
AU2002357012A1
(en)
|
2001-11-27 |
2003-06-10 |
Transform Pharmaceuticals, Inc. |
Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
|
CN1310652C
(zh)
|
2001-11-29 |
2007-04-18 |
特拉科斯有限公司 |
用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
|
DK1344533T3
(da)
|
2002-03-15 |
2007-01-08 |
Natimmune As |
Farmaceutiske præparater, der omfatter mannosebindende lectin
|
AU2003224916B2
(en)
|
2002-04-10 |
2009-01-08 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
FI2206517T3
(fi)
|
2002-07-03 |
2023-10-19 |
Ono Pharmaceutical Co |
Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
|
ES2358730T3
(es)
|
2002-07-15 |
2011-05-13 |
Board Of Regents, The University Of Texas System |
Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
|
EP1551392A4
(en)
|
2002-09-17 |
2006-09-20 |
Arqule Inc |
NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF
|
WO2004035607A2
(en)
|
2002-10-17 |
2004-04-29 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
TWI323662B
(en)
|
2002-11-15 |
2010-04-21 |
Telik Inc |
Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
|
AR042052A1
(es)
|
2002-11-15 |
2005-06-08 |
Vertex Pharma |
Diaminotriazoles utiles como inhibidores de proteinquinasas
|
IS6633A
(is)
|
2002-11-22 |
2004-05-23 |
Omega Farma Ehf. |
Samsetningar af fínasteríð töflum
|
AU2004256425A1
(en)
*
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
AU2004259398A1
(en)
|
2003-06-27 |
2005-02-03 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050049207A1
(en)
|
2003-09-03 |
2005-03-03 |
Kaufmann Doug A. |
Method of treating and preventing cancer
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
BRPI0416141B8
(pt)
|
2003-11-01 |
2021-05-25 |
Biovation Ltd |
anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
|
PT1706133E
(pt)
|
2003-12-02 |
2010-12-07 |
Cleveland Clinic Foundation |
Métodos para protecção contra radiação utilizando flagelina
|
KR101170655B1
(ko)
|
2003-12-11 |
2012-08-03 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
세포 증식 질환 치료용 화합물
|
DE10359828A1
(de)
|
2003-12-12 |
2005-07-28 |
Zoser B. Dr.Rer.Nat. Salama |
CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
|
EP1748772A2
(en)
|
2004-04-09 |
2007-02-07 |
University Of South Florida |
Combination therapies for cancer and proliferative angiopathies
|
JP2004224802A
(ja)
|
2004-04-21 |
2004-08-12 |
Japan Science & Technology Agency |
抗菌剤
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー/エス |
ヒト抗−kir抗体
|
EP1768977A2
(en)
|
2004-07-02 |
2007-04-04 |
ICOS Corporation |
Compounds useful for inhibiting chk1
|
KR20070038557A
(ko)
|
2004-07-22 |
2007-04-10 |
제넨테크, 인크. |
Her2 항체 조성물
|
DE602005017283D1
(de)
|
2004-08-18 |
2009-12-03 |
Astrazeneca Ab |
Ausgewählte kondensierte heterocyclen und deren anwendung
|
JP2008519036A
(ja)
|
2004-11-08 |
2008-06-05 |
バクスター・インターナショナル・インコーポレイテッド |
チューブリン阻害化合物のナノ粒子組成物
|
EP1885352A2
(en)
|
2004-11-24 |
2008-02-13 |
Novartis AG |
Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
|
WO2006065894A2
(en)
|
2004-12-14 |
2006-06-22 |
University Of South Florida |
Methods for inhibiting stat3 signaling in immune cells
|
WO2006071812A2
(en)
|
2004-12-23 |
2006-07-06 |
H. Lee Moffitt Cancer Center And Research Institute |
Platinum iv complex inhibitor
|
CA2599393A1
(en)
|
2005-02-25 |
2006-08-31 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of stat3 and the uses thereof
|
JP2006248978A
(ja)
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
JP2006290871A
(ja)
|
2005-03-16 |
2006-10-26 |
Taheebo Japan Kk |
抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
|
US20060252073A1
(en)
|
2005-04-18 |
2006-11-09 |
Regents Of The University Of Michigan |
Compositions and methods for the treatment of cancer
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US20070009532A1
(en)
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
AR057579A1
(es)
|
2005-11-23 |
2007-12-05 |
Merck & Co Inc |
Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
|
JP2007145680A
(ja)
|
2005-11-30 |
2007-06-14 |
Idemitsu Kosan Co Ltd |
水素発生材料および水素発生方法
|
AU2006329681A1
(en)
|
2005-12-24 |
2007-07-05 |
Biotica Technology Ltd. |
21-deoxymacbecin analogues useful as antitumor agents
|
AU2007208494A1
(en)
|
2006-01-12 |
2007-08-02 |
Merck Sharp & Dohme Corp. |
Fluorinated arylamide derivatives
|
CA2635797C
(en)
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
WO2007100640A2
(en)
|
2006-02-21 |
2007-09-07 |
The Regents Of The University Of Michigan |
Growth hormone receptor antagonist cancer treatment
|
WO2007095753A1
(en)
|
2006-02-24 |
2007-08-30 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
|
RU2456265C2
(ru)
|
2006-03-31 |
2012-07-20 |
Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем |
Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
|
US20070238770A1
(en)
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
WO2008094321A2
(en)
|
2006-10-04 |
2008-08-07 |
Universtiy Of South Florida |
Akt sensitization of cancer cells
|
WO2008077062A2
(en)
|
2006-12-19 |
2008-06-26 |
Board Of Regents, The University Of Texas System |
Suppression of stat3 reactivation after src kinase inhibition to treat cancer
|
JP4077863B1
(ja)
|
2007-05-31 |
2008-04-23 |
タヒボジャパン株式会社 |
抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法
|
AU2008266951B2
(en)
|
2007-06-18 |
2013-12-12 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
CN105018492B
(zh)
|
2007-08-27 |
2018-08-24 |
北京强新生物科技有限公司 |
不对称干扰rna的组合物及其用途
|
WO2009036099A1
(en)
|
2007-09-10 |
2009-03-19 |
Boston Biomedical, Inc. |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
US20100298402A1
(en)
|
2007-11-06 |
2010-11-25 |
Orchid Research Laboratories Limited |
Stilbene derivatives as pstat3/il-6 inhibitors
|
CA2706931C
(en)
*
|
2007-12-06 |
2015-05-12 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
CA2939492C
(en)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Anti-human cd52 immunoglobulins
|
US8267122B2
(en)
|
2009-06-30 |
2012-09-18 |
Ge Aviation Systems Llc |
Method and systems for bleed air supply
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
WO2011084694A1
(en)
|
2009-12-17 |
2011-07-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Stabilized stat3 decoy oligonucleotides and uses therefor
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
CN107721958A
(zh)
|
2010-03-19 |
2018-02-23 |
北京强新生物科技有限公司 |
靶向癌症干细胞的新的化合物和组合物
|
RU2591823C2
(ru)
*
|
2010-03-19 |
2016-07-20 |
Бостон Байомедикал, Инк. |
Новые способы направленного воздействия на раковые стволовые клетки
|
BR122021025776B1
(pt)
*
|
2010-03-19 |
2022-12-27 |
Boston Biomedical, Inc. |
Composição compreendendo compostos de naftofurano e uso da mesma para tratar câncer
|
AU2015218436B9
(en)
|
2010-03-19 |
2017-03-09 |
Boston Biomedical, Inc. |
Novel Methods For Targeting Cancer Stem Cells
|
JP5208239B2
(ja)
|
2010-09-29 |
2013-06-12 |
タヒボジャパン株式会社 |
アルキンカップリングによる抗がん活性三環式化合物の新規製法
|
JP6047404B2
(ja)
*
|
2011-02-01 |
2016-12-21 |
株式会社カネカ |
生理活性物質含有水溶化製剤、及びその製法
|
CN103402993A
(zh)
|
2011-03-04 |
2013-11-20 |
舟山海中洲新生药业有限公司 |
用于疾病治疗的4,9-二羟基-萘并[2,3-b] 呋喃新型酯
|
LT2691112T
(lt)
|
2011-03-31 |
2018-07-25 |
Merck Sharp & Dohme Corp. |
Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
|
US8977803B2
(en)
|
2011-11-21 |
2015-03-10 |
Western Digital Technologies, Inc. |
Disk drive data caching using a multi-tiered memory
|
WO2013166618A1
(en)
|
2012-05-08 |
2013-11-14 |
Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. |
PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
|
WO2013172918A1
(en)
|
2012-05-15 |
2013-11-21 |
University Of Southern California |
Ksr1 gene polymorphism for use in predicting outcome and therapy selection
|
CN104470949A
(zh)
|
2012-05-15 |
2015-03-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
SG11201508358RA
(en)
|
2013-04-09 |
2015-11-27 |
Boston Biomedical Inc |
2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
|
JP6199787B2
(ja)
|
2014-03-28 |
2017-09-20 |
京セラドキュメントソリューションズ株式会社 |
画像形成装置
|
CN105658209A
(zh)
|
2013-09-13 |
2016-06-08 |
拜耳制药股份公司 |
含有瑞法美替的药物组合物
|
TW201622731A
(zh)
|
2014-04-08 |
2016-07-01 |
泰瓦藥品工業有限公司 |
包含恩曲他濱(Emtricitabine)、替諾福韋(Tenofovir)、地瑞那韋(Darunavir)及利托那韋(Ritonavir)之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
|
WO2015190489A1
(ja)
|
2014-06-09 |
2015-12-17 |
京都薬品工業株式会社 |
新規抗癌剤
|
JP2016016973A
(ja)
|
2014-07-10 |
2016-02-01 |
株式会社リコー |
シート処理装置
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
EP3110447B1
(en)
|
2014-09-16 |
2020-04-29 |
Synermore Biologics Co., Ltd. |
Anti-egfr antibody and uses of same
|
EP3283071A1
(en)
|
2015-04-17 |
2018-02-21 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
MX2017013358A
(es)
|
2015-04-17 |
2018-08-01 |
Boston Biomedical Inc |
Métodos para tratar el cáncer.
|
EA201792287A1
(ru)
|
2015-04-17 |
2018-03-30 |
Бостон Биомедикал, Инк. |
Способы лечения рака
|
US20180250261A1
(en)
|
2015-04-27 |
2018-09-06 |
Boston Biomedical, Inc. |
Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
CN109069469A
(zh)
|
2016-01-20 |
2018-12-21 |
北京强新生物科技有限公司 |
治疗癌症的方法
|
WO2018096401A1
(en)
|
2016-11-22 |
2018-05-31 |
Hitoshi Ban |
New naphtho[2,3-b]furan derivatives
|
WO2018183089A1
(en)
|
2017-03-30 |
2018-10-04 |
Boston Biomedical, Inc. |
Compositions for treating and/or preventing cancer
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
がんを処置するための方法
|